Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions

Company to achieve 2030 Scope 1 and 2 greenhouse gas emissions reduction target of 30% ahead of schedule; increases ambition to 50% reduction, aligned with 1.5˚C pathway

Thermo Fisher Scientific Inc . (NYSE: TMO), the world leader in serving science, today announced a new 2030 greenhouse gas emissions reduction target to reduce its Scope 1 and 2 emissions from operations by more than 50% from a 2018 baseline. 1 The company is on track to achieve its previous 2030 goal of a 30% reduction, ahead of schedule.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221206005156/en/

(Photo: Business Wire)

(Photo: Business Wire)

The company's new 50% reduction target fulfills its commitment to the Business Ambition to 1.5˚C campaign and aligns its climate strategy with the Paris Agreement and its reduction targets with the 1.5˚C pathway. This represents an important milestone in Thermo Fisher's pursuit of a net-zero value chain by 2050 , which includes Scope 1, 2 and 3 emissions. The company has submitted its targets to the Science Based Targets initiative for validation.

"Our net-zero goal reflects Thermo Fisher's commitment to environmental sustainability across the company," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Delivering on interim targets in an accelerated timeframe is a testament to our colleagues and the investments behind our ongoing climate strategy. Our ambitious new 2030 target on the path to net-zero emissions by 2050 reinforces our Mission to enable our customers to make the world healthier, cleaner and safer."

The company has taken a multi-pronged approach in pursuit of net-zero emissions by:

  • Transitioning away from fossil fuels and accelerating the adoption of renewable electricity to power its facilities . Currently, more than 100 Thermo Fisher sites across the globe use 100% renewable electricity. Earlier this year, the company entered into an agreement with Enel North America to source half of its U.S. electricity needs from wind power .
  • Engaging with 90% of suppliers 2 — its largest source of Scope 3 emissions — to set science-based targets by 2027 , helping to reduce emissions across its global value chain in support of the world's climate goals.
  • Designing products with the environment in mind . Thermo Fisher's greener product alternatives and ENERGY STAR certified products help scientists advance sustainability in the lab by minimizing the use of hazardous chemicals, decreasing waste and material consumption, and increasing energy efficiency.

More information about the company's environmental, social and governance progress can be found at www.thermofisher.com/csr .

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

______________
1 New target is 50.4%. Both targets from a 2018 baseline
2 By spend

Media Contact:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com

Investor Contact:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Cardiologist wearing virtual reality glasses.

Top 3 Medical Device ETFs for Investors in 2026

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...

Interactive Chart

Latest Press Releases

Related News